<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66035">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246205</url>
  </required_header>
  <id_info>
    <org_study_id>PAUDA</org_study_id>
    <nct_id>NCT02246205</nct_id>
  </id_info>
  <brief_title>RANDOMIZED CLINICAL TRIAL COMPARING POSTOPERATIVE MORBIDITY ON RECONSTRUCTION AFTER PANCREATICODUODENECTOMY(PAUDA)</brief_title>
  <acronym>PAUDA</acronym>
  <official_title>RANDOMIZED CLINICAL TRIAL COMPARING POSTOPERATIVE MORBIDITY ON RECONSTRUCTION AFTER PANCREATICODUODENECTOMY BETWEEN TWO RECONSTRUCTION TECHNIQUES (PAUDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the effect of Roux-en Y reconstruction (study group,
      DPCDA) versus classical Child reconstruction (DPCUN) in the incidence of VGL in patients for
      DPC. The hypotesis of the study is that Roux-en Y reconstruction decreases incidence of DGE
      after pancreaticoduodenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pancreaticoduodenectomy (DPC) is the procedure of choice of the tumors of the head of
      the pancreas, periampullary tumors and intractable inflammatory pathology.

      The high postoperative morbidity (50%) involve a mean hospital stay of 15 days after
      surgery. The most common complication is delayed gastric emptying (DGE), defined as the
      intolerance to solid oral intake by 7th day postoperative. In some severe cases, oral
      intolerance can occur after the 21th postoperative day. Therefore, the patient requires
      parenteral nutrition and prolonged hospital stay.

      The aim of the study is to compare the effect of Roux-en Y reconstruction (study group,
      DPCDA) versus classical Child reconstruction (DPCUN) in the incidence of VGL in patients for
      DPC.

      The hypotesis of the study is that Roux-en Y reconstruction decreases incidence of DGE after
      pancreaticoduodenectomy.

      A pilot randomized clinical trial has been designed to compare two surgical techniques for
      reconstruction of digestive tract after DPC in patients treated in our center. The patients
      are randomized after tumor resection and before the reconstruction througt
      computer-generated random numbers using a sealed envelope technique. The primary endpoint is
      the incidence of DGE. Secondary endpoints are postoperative morbidity and specific
      complications as pancreatic fistula, the hospital stay, and postoperative endocrine and
      exocrine function.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delayed gastric emptying incidence after pancreaticoduodenectomy</measure>
    <time_frame>within the first 60 daysafter surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity and complications after pancreaticoduodenectomy</measure>
    <time_frame>within the first 60 daysafter surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Malignant Neoplasm of Head of Pancreas</condition>
  <arm_group>
    <arm_group_label>DPC DN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roux-en Y reconstruction after pancreaticoduodenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPC UN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Child reconstruction after pancreaticoduodenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreaticoduodenectomy</intervention_name>
    <description>Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.</description>
    <arm_group_label>DPC DN</arm_group_label>
    <arm_group_label>DPC UN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pancreatic head cancer considered resectable after the extension study

          -  Patients suffering from tumors considered resectable periampullary after the
             extension study

          -  Patients suffering from pancreatic inflammatory disease with medically intractable
             pain

          -  Patients who have read the information sheet of the study and signed the informed
             consent form

        Exclusion Criteria:

          -  Patients undergoing previous gastrectomy

          -  Patients with refusal to initiate the study.

          -  Patients with unresectable cancer with criteria for inoperability as the presence of
             metastasis, invasion artery (superior mesenteric artery, celiac axis or hepatic
             artery), venous obliteration, or invasion of other organs by contiguity (except
             duodenum.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JULI BUSQUETS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juli Busquets Barenys</last_name>
    <phone>932607500</phone>
    <phone_ext>2641</phone_ext>
    <email>jbusquets@bellvitgehospital.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SILVIA MARTIN</last_name>
      <phone>636830993</phone>
      <email>silviamartin1985@gmail.com</email>
    </contact>
    <investigator>
      <last_name>SILVIA MARTIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 18, 2014</lastchanged_date>
  <firstreceived_date>September 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>JULI BUSQUETS BARENYS</investigator_full_name>
    <investigator_title>Medicine Doctor</investigator_title>
  </responsible_party>
  <keyword>pancreaticoduodenectomy</keyword>
  <keyword>delayed gastric emptying</keyword>
  <keyword>Roux en-Y reconstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
